2-[({2-[6-({[(3-fluoro-2-pyridyl)cyclobutyl]methyl}amino)pyridazin-3-yl]-1,3-thiazol-5-yl}methyl)amino]ethan-1-ol;

N-({2-[6-({[(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)pyridazin-3-yl](1,3-thiazol-5-yl)}methyl)-2-hydroxy-N-methylacetamide;

[N-({2-[6-({[(3-fluoro-2-pyridyl)cyclobutyl]methyl}amino)pyridazin-3-yl]-1,3-thiazol-5-yl}methyl)carbamoyl]methyl (2S)-2-((2S)-2-aminopropanoylamino)propanoate; and

[N-({2-[6-({[(3-fluoro-2-pyridyl)cyclobutyl]methyl}amino)pyridazin-3-yl]-1,3-thiazol-5-yl}methyl)carbamoyl]methyl (2S)-2-((2S)-2-amino-3-methylbutanoylamino)-3-methylbutanoate;

or a pharmaceutically acceptable salt thereof.

48. A pharmaceutical composition comprising a compound of any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof.

49. The pharmaceutical composition of claim 48, wherein the pharmaceutical composition is formulated as a tablet.

50. The pharmaceutical composition of claim 48, wherein the pharmaceutical composition is formulated as a capsule.

51. The use of a compound of any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a disease selected from Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) and myasthenia gravis.

2-[({2-[6-({[(3-fluoro-2-pyridyl)cyclobutyl]methyl}amino)pyridazin-3-yl]-1,3-thiazol-5-yl}methyl)amino]ethan-1-ol;

N-({2-[6-({[(3-fluoro(2-pyridyl))cyclobutyl]methyl}amino)pyridazin-3-yl](1,3-thiazol-5-yl)}methyl)-2-hydroxy-N-methylacetamide;

[N-({2-[6-({[(3-fluoro-2-pyridyl)cyclobutyl]methyl}amino)pyridazin-3-yl]-1,3-thiazol-5-yl}methyl)carbamoyl]methyl (2S)-2-((2S)-2-aminopropanoylamino)propanoate; and

[N-({2-[6-({[(3-fluoro-2-pyridyl)cyclobutyl]methyl}amino)pyridazin-3-yl]-1,3-thiazol-5-yl}methyl)carbamoyl]methyl (2S)-2-((2S)-2-amino-3-methylbutanoylamino)-3-methylbutanoate;

or a pharmaceutically acceptable salt thereof.

48. A pharmaceutical composition comprising a compound of any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof.

49. The pharmaceutical composition of claim 48, wherein the pharmaceutical composition is formulated as a tablet.

50. The pharmaceutical composition of claim 48, wherein the pharmaceutical composition is formulated as a capsule.

51. The use of a compound of any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a disease selected from Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA) and myasthenia gravis.

52. The use of a compound of any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of chronic obstructive pulmonary disease (COPD).

53. The use of a compound of any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of heart failure.

54. The use of a compound of any one of claims 1 to 47, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of frailty.